Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?
- 1 March 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (3), 345-351
- https://doi.org/10.1373/clinchem.2005.059832
Abstract
Background: Although multiple serum-based tumor markers have been described for breast cancer, such as CA 15-3, BR 27.29 (CA27.29), carcinoembryonic antigen (CEA), tissue polypeptide antigen, tissue polypeptide specific antigen, and HER-2 (the extracellular domain), the most widely used are CA 15-3 and CEA.Keywords
This publication has 67 references indexed in Scilit:
- New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapyAnnals of Oncology, 2005
- Monitoring of Serum Her-2/ neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast CancerClinical Cancer Research, 2004
- Follow-up care of patients treated for breast cancer: a structured reviewCancer Treatment Reviews, 2004
- Ca 15-3 in the follow-up of localised breast cancer: a prospective studyEuropean Journal Of Cancer, 2002
- Tumour marker measurements in the diagnosis and monitoring of breast cancerCancer Treatment Reviews, 2000
- The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markersEuropean Journal Of Cancer, 1999
- CA-15.3: Prognostic factor in breast cancerEuropean Journal Of Cancer, 1998
- Gestational trophoblastic diseases and their treatmentCancer Treatment Reviews, 1997
- Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseasesBreast Cancer Research and Treatment, 1989
- Assessment of response to therapy in advanced breast cancerEuropean Journal of Cancer (1965), 1977